• Rimonabant as a CB1 Control in Pain Studies

  2026-09-02

  Rimonabant (SR141716) offers a selective CB1 challenge for determining whether cannabinoid-associated pain phenotypes arise through CB1 or alternative pathways. This article connects its receptor pharmacology with recent terpene analgesia findings to develop a more rigorous assay strategy for neurobiology and obesity research.

• ATG4B, Energy Deficiency, and AML DNA Repair

  2026-09-02

  A 2025 Advanced Science study identifies nuclear translocation of ATG4B as a molecular link between energy deficiency, impaired PRMT1–MRE11 DNA repair, and acute myeloid leukemia progression. By combining mechanistic cell studies with genetically induced AML models and patient-derived xenografts, the work suggests that ATG4B inhibition may reduce genomic instability and malignant expansion, although clinical translation remains unresolved.

• Meropenem: Mechanism, Evidence, and Research Use

  2026-09-01

  Meropenem is a β-lactam antibiotic carbapenem with broad in-vitro activity against important Gram-negative and Gram-positive bacteria. Its PBP-directed mechanism, resistance-modeling value, and formulation limits make it useful for controlled antibacterial research rather than unsupervised medical use.

• ATRX-Deficient Glioma Sensitivity to RTK Inhibitors

  2026-09-01

  The reference study identifies a genotype-linked vulnerability in high-grade glioma: ATRX-deficient cells are more sensitive to several multi-targeted receptor tyrosine kinase and PDGFR inhibitors than ATRX-proficient counterparts. Its combination data further suggest that pairing RTK inhibition with temozolomide may create a stronger treatment response, supporting ATRX status as a useful variable in translational studies and clinical-trial analysis.

• GDC-0994: From ERK Signal to Disease Phenotype

  2026-08-31

  GDC-0994 is a selective ERK1/2 inhibitor for connecting pathway pharmacology with measurable cancer and cholestatic phenotypes. This article presents an assay-centered framework for interpreting ERK phosphorylation, downstream signaling, bile-acid transport, and tumor-cell responses without conflating pathway modulation with therapeutic proof.

• Sulfo-NHS-SS-Biotin Kit: Reversible Labeling

  2026-08-31

  Sulfo-NHS-SS-Biotin is a water-soluble, amine-reactive reagent for reversible protein and cell-surface labeling. Its NHS ester targets primary amines, while its disulfide spacer permits reductive release of the biotin label.

• SIRT1, Mitochondrial Biogenesis, and Prion Toxicity

  2026-08-30

  Zhao and colleagues identify a SIRT1–PGC-1α–TFAM pathway that links prion peptide toxicity to impaired mitochondrial biogenesis in N2a neuroblastoma cells. Their findings show that SIRT1 activation, including pharmacological activation by Resveratrol, can improve mitochondrial integrity and reduce apoptosis, while also defining important limits for translation beyond this cellular model.

• Dual-Metric In Vitro Evaluation of Cancer Drug Responses

  2026-08-29

  Hannah R. Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a dual-metric framework that separates proliferative arrest from cell death, improving interpretation of dose and time-dependent responses in cancer biology research.

• Quercetin Protects Cataract Lenses via Hippo Signaling

  2026-08-28

  The reference study identifies Hippo pathway modulation as a potential mechanism through which quercetin protects lens epithelial cells from oxidative cataract injury. By combining network pharmacology with UVB-induced cataract models, H2O2-injured cells, and α-hederin rescue experiments, it links reduced oxidative stress and improved epithelial survival to Hippo pathway suppression.

• Sorafenib (BAY-43-9006) Workflow Guide

  2026-08-28

  Build cleaner oncology assays with Sorafenib by separating direct tumor-cell effects from VEGFR-linked antiangiogenic activity. This workflow combines dose-response design, endothelial tube formation, pathway readouts, and reference-study benchmarking for more interpretable cancer biology research.

• GS967: Cardiac Late Sodium Current Inhibitor

  2026-08-27

  GS967 supports a connected workflow from ventricular myocyte sodium-current recording to calcium handling, repolarization, and whole-heart arrhythmia assays. Its concentration- and voltage-dependent activity makes it useful for testing whether pathological late sodium influx is a causal driver rather than merely a correlate of cardiac dysfunction.

• Fludarabine: Designing Decision-Grade DNA Assays

  2026-08-27

  Fludarabine is a DNA synthesis inhibitor that can do more than establish cytotoxicity in oncology models. This guide presents a decision-grade assay framework linking replication stress, apoptosis, genotype-aware model selection, and translational interpretation.

• Cannabis Terpenes Activate A2A Receptors in Neuropathic Pain

  2026-08-26

  Schwarz et al. show that several Cannabis sativa terpenes reduce pain-related behavior in mouse models of chemotherapy-induced neuropathy and inflammatory pain through an adenosine A2A receptor-dependent mechanism. The combination of behavioral pharmacology, spinal CRISPR knockdown, cAMP and binding assays, and molecular modeling provides a mechanistic framework for evaluating non-cannabinoid terpene analgesia.

• NPT1-Mediated PAH Transport and Faropenem

  2026-08-26

  The reference study provided the first molecular evidence that human renal NPT1 can transport p-aminohippuric acid (PAH) across the apical membrane of proximal-tubule cells. Its chloride sensitivity, substrate inhibition profile, and recognition of faropenem connect phosphate-transporter biology with renal handling of organic anions, while also defining important limits for interpreting antibiotic experiments.

• Peptidisc-Assisted Multimeric Nanobody Engineering

  2026-08-25

  Chen and Duong van Hoa describe a peptidisc-assisted hydrophobic clustering strategy that converts engineered nanobodies into soluble multimeric, bispecific, and autofluorescent assemblies. The preprint links multivalency to stronger functional binding and suggests a modular alternative to tandem fusion, self-assembly domains, and chemical cross-linking.

8504 records 1/567 page Next 12345 下5页 Last page